- Home
- BDTX vs CFBK Comparison
BDTX vs CFBK Comparison
Compare BDTX & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | CFBK |
|---|---|---|
| Founded | 2014 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 178.1M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BDTX | CFBK |
|---|---|---|
| Price | $1.68 | $35.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $9.67 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 929.0K | 64.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ 130.71 | 30.58 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $31.99 |
| Revenue Next Year | N/A | $9.09 |
| P/E Ratio | ★ N/A | $46.51 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $22.10 |
| 52 Week High | $4.94 | $36.95 |
Technical Indicators
Market Signals| Indicator | BDTX | CFBK |
|---|---|---|
| Relative Strength Index (RSI) | 37.69 | 75.14 |
| Support Level | $1.60 | $32.20 |
| Resistance Level | $1.90 | N/A |
| Average True Range (ATR) | 0.09 | 1.06 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 7.81 | 79.48 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.